Department of Epidemiology, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
PLoS One. 2019 Jan 15;14(1):e0198449. doi: 10.1371/journal.pone.0198449. eCollection 2019.
Liver cirrhosis mortality number has increased over the last decades. We aimed to estimate the liver cirrhosis mortality rate and its trends for the first time by sex, age, geographical distribution, and cause in Iran.
Iranian Death Registration System, along with demographic (Complete and Summary Birth History, Maternal Age Cohort and Period methods) and statistical methods (Spatio-temporal and Gaussian process regression models) were used to address the incompleteness and misclassification and uncertainty of death registration system to estimate annual cirrhosis mortality rate. Percentages of deaths were proportionally redistributed into cirrhosis due to hepatitis B, C and alcohol use based on the data from the Global Burden of Disease (GBD) 2010 study.
Liver cirrhosis mortality in elder patients was 12 times higher than that in younger patients at national level in 2015. Over the 26 years, liver cirrhosis mortality in males has increased more than that in females. Plus, the percentage of change in age adjusted mortality rate at provincial levels varied between decreases of 64.53% to nearly 17% increase. Mortality rate has increased until 2002 and then decreased until 2015.The province with highest mortality rate in 2015 has nearly two times greater rate compare to the lowest. More than 60% of liver cirrhosis mortality cases at national level are caused by hepatitis B and C infection. The rate of hepatitis B mortality is four times more than that from hepatitis C.
This study demonstrated an increasing and then decreasing pattern in cirrhosis mortality that could be due to national vaccination of hepatitis B program. However monitoring, early detection and treatment of risk factors of cirrhosis, mainly in high risk age groups and regions are essential. Cirrhosis mortality could be diminished by using new non-invasive methods of cirrhosis screening, hepatitis B vaccination, definite treatment of hepatitis C.
在过去几十年中,肝硬化死亡率有所增加。我们旨在首次按性别、年龄、地理分布和病因估计伊朗的肝硬化死亡率及其趋势。
使用伊朗死亡登记系统以及人口统计学方法(完整和摘要出生史、孕产妇年龄队列和时期方法)和统计方法(时空和高斯过程回归模型)来解决死亡登记系统的不完整性、分类错误和不确定性,以估计肝硬化的年死亡率。根据 2010 年全球疾病负担研究(GBD)的数据,将因乙型肝炎、丙型肝炎和酒精使用导致的肝硬化死亡比例按比例重新分配。
2015 年,全国范围内老年患者的肝硬化死亡率是年轻患者的 12 倍。在过去的 26 年中,男性肝硬化死亡率的增长速度超过了女性。此外,省级年龄调整死亡率变化率的百分比在下降 64.53%到近 17%的增长之间变化。死亡率从 2002 年开始上升,然后在 2015 年下降。2015 年死亡率最高的省份的死亡率几乎是死亡率最低的省份的两倍。在全国范围内,超过 60%的肝硬化死亡病例是由乙型肝炎和丙型肝炎感染引起的。乙型肝炎死亡率是丙型肝炎的四倍。
本研究表明肝硬化死亡率呈先增加后减少的模式,这可能是由于国家乙型肝炎疫苗接种计划。然而,监测、早期发现和治疗肝硬化的危险因素,特别是在高风险年龄组和地区,至关重要。通过使用新的非侵入性肝硬化筛查方法、乙型肝炎疫苗接种和丙型肝炎的明确治疗,可以降低肝硬化死亡率。